TF and neoplasm: To identify a targetable surface molecule for TNBC therapy, we demonstrated that tissue factor (TF) is a novel, common yet selective oncotarget on the TNBC cancer cells (50% to 85% of 161 patients with TNBC) and tumor VECs (64% of 14 patients with TNBC)14.